Home Ingredients effera® (Human-Identical Lactoferrin)
Immune SupportGut Health

effera® (Human-Identical Lactoferrin)

Evidence Level
Limited
4 Clinical Trials
2 Documented Benefits
2/5 Evidence Score

effera® (Helaina) is a human-identical lactoferrin made by yeast fermentation (Komagataella phaffii). Its amino acid sequence matches the lactoferrin in human breast milk, while its sugar side chains differ, and it is not made from cow's milk like the bovine lactoferrin in most supplements. Lactoferrin is an iron-binding protein that slows bacteria, fungi and some viruses in laboratory tests. Two maker-funded reports of one 28-day trial in 66 healthy adults are published: effera did not raise antibodies against lactoferrin, while bovine lactoferrin roughly tripled them, and some gut bacteria and fecal fatty acid proportions shifted, results the authors call exploratory. No trial has tested effera on infections or immune outcomes. The infection evidence for lactoferrin comes from trials of other lactoferrin products, not effera, and it is not known whether it carries over.

Studied Dose 0.34 g or 3.4 g a day for 28 days in the one effera trial (66 healthy adults). The infection trials cited here did not use effera.
Active Compound Human-identical lactoferrin (hLF), effera® by Helaina, made by precision fermentation in the yeast Komagataella phaffii. Its amino acid sequence is identical to human lactoferrin; its glycans are mainly oligomannose types that differ from human milk lactoferrin. Not derived from cow's milk.

Benefits

Immune support (evidence is from other lactoferrin products)

A pooled analysis of 6 randomized trials with 1,194 people found lower odds of respiratory infections with lactoferrin (odds ratio 0.57); two included studies had a high risk of bias. None of those trials used effera, which has not itself been tested on infections or immune function, so whether the human-identical form works the same, better or worse is unknown.

Supported by Trial 3

Gut bacteria and fecal short-chain fatty acids

In a 28-day trial in 66 healthy adults, effera kept gut bacterial diversity stable, raised some bacteria such as Faecalibacterium at 3.4 g a day, and increased acetate as a share of fecal fatty acids. Bovine lactoferrin raised total short-chain fatty acids. The maker-funded authors call these exploratory findings, and no digestive symptoms were reported as outcomes.

Supported by Trial 2

Mechanism of action

1

Iron binding and immune cell signaling

Lactoferrin binds iron tightly, which in laboratory tests deprives some bacteria of iron, and it also has antiviral and antifungal activity in lab studies. It interacts with immune cells, but whether effera's human sequence acts differently from bovine lactoferrin in the body has not been tested. This is a proposed mechanism, not a demonstrated effect.

Clinical trials

1
effera versus bovine lactoferrin: antibodies and safety
PubMed

Randomized, double-blind, parallel-arm trial: effera 0.34 g or 3.4 g a day, or bovine lactoferrin 3.4 g a day, for 28 days, with follow-up to day 84; plus a 24-person observational comparison group. Funded by Helaina. (Peterson et al. 2025, Int J Toxicol)

66 healthy adults.

Antibodies against bovine lactoferrin rose about 3-fold by day 56 in the bovine group, while antibodies against human lactoferrin did not change with either effera dose. Safety blood tests stayed within normal ranges in all groups. The trial measured antibodies and safety, not infections, symptoms or immune function.

2
effera and the adult gut microbiome
PubMed

Randomized, double-blind, parallel-arm trial with the same doses and participants as the antibody study; stool samples on days 0, 28, 56 and 84. Pre-specified exploratory outcome. Some authors are Helaina employees. (Peterson et al. 2026, J Diet Suppl)

66 healthy adults.

Gut bacterial diversity stayed stable. effera was linked to increases in Lachnospira, Paraprevotella and Faecalibacterium at the high dose and a higher proportion of acetate; bovine lactoferrin raised total short-chain fatty acids. The authors describe the findings as hypothesis-generating.

3
Lactoferrin and respiratory infections, meta-analysis
PubMed

Systematic review of 9 randomized trials, 6 pooled in a meta-analysis. (Ali et al. 2021, Clin Nutr ESPEN)

1,194 participants across 6 pooled trials of lactoferrin, none using effera.

Lactoferrin was linked to lower odds of developing a respiratory infection (odds ratio 0.57, 95% CI 0.44 to 0.74). Two included studies had a high risk of bias. None tested effera.

4
Bovine lactoferrin with an immunoglobulin-rich whey fraction for colds
PubMed

Double-blind randomized placebo-controlled trial: 600 mg a day of a bovine lactoferrin and whey immunoglobulin combination for 90 days. (Vitetta et al. 2013, Complement Ther Med)

126 adults who reported frequent colds; 90 completed 90 days.

Fewer colds were recorded on the combination (48 versus 112, p<0.001), but total days sick and cold severity were not significantly different. The lactoferrin's own share of the effect cannot be separated, and effera was not used.

Side effects and drug interactions

Common Potential side effects

In a 28-day trial in 66 healthy adults at up to 3.4 g a day, safety blood tests stayed normal and effera did not raise antibodies against lactoferrin, while bovine lactoferrin did. There is no long-term human safety data.
Not made from cow's milk. The maker's allergy assessment was done by computer sequence comparison and simulated digestion, not by testing people with milk allergy, so anyone with a milk allergy should ask their doctor first.
The maker's assessment identified 36 residual yeast proteins in the ingredient and found no match to known allergens.

Important Drug interactions

Iron supplements: lactoferrin binds iron strongly, so take iron and lactoferrin at different times of day
No drug interaction studies have been done on effera®, so interactions have not been ruled out; tell your doctor if you take prescription medicines

More Immune Support Ingredients

Immune Support
Vitamin C
Vitamin C (L-ascorbic acid) is a water-soluble vitamin that humans cannot make, so it must…
Immune Support
Wellmune (Yeast Beta-Glucan)
Wellmune is a baker's yeast beta-1,3/1,6-D-glucan derived from a proprietary strain of Sac…
Immune Support
Zinc
Zinc is an essential trace mineral that hundreds of enzymes need, and it plays a role in i…
Immune Support
Quercetin
Quercetin is a plant flavonoid found in onions, apples and capers, and it is a popular sup…

Explore Other Ingredients

Anti-Inflammatory
Bromelain
Bromelain is a group of protein-digesting enzymes from the pineapple stem. Its most consis…
Metabolic Health
Inulin
Inulin is a soluble prebiotic fiber found naturally in chicory root, agave, and many veget…
Immune Support
Probiotics (Multi-strain Blends)
Multi-strain probiotic blends combine live microbes, usually from Lactobacillus and Bifido…

Related articles from our blog

📝 Article
Effera and the Gut Barrier: What the New Human-Lactoferrin Data Really Shows
Every so often a genuinely new kind of ingredient shows up, not a new blend or a new dose but a new way of making a fami…
July 29, 2026

Frequently asked questions about effera® (Human-Identical Lactoferrin)

What is effera?

effera® (Helaina) is a human-identical lactoferrin made by yeast fermentation (Komagataella phaffii). Its amino acid sequence matches the lactoferrin in human breast milk, while its sugar side chains differ, and it is not made from cow's milk like the bovine lactoferrin in most supplements.

What is effera used for?

effera is researched primarily for Immune Support and Gut Health. A pooled analysis of 6 randomized trials with 1,194 people found lower odds of respiratory infections with lactoferrin (odds ratio 0.57); two included studies had a high risk of bias.

What is the recommended dosage of effera?

The clinically studied dose is 0.34 g or 3.4 g a day for 28 days in the one effera trial (66 healthy adults). The infection trials cited here did not use effera. Always follow the product label and check with a healthcare provider for personal advice.

Is effera safe, and does it have side effects?

For most healthy adults, effera is well tolerated at studied doses. Reported effects can include: In a 28-day trial in 66 healthy adults at up to 3.4 g a day, safety blood tests stayed normal and effera did not raise antibodies against lactoferrin, while bovine lactoferrin did. There is no long-term human safety data. Not made from cow's milk. It may also interact with some medications. effera is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does effera interact with any medications?

Possible interactions include: Iron supplements: lactoferrin binds iron strongly, so take iron and lactoferrin at different times of day No drug interaction studies have been done on effera®, so interactions have not been ruled out; tell your doctor if you take prescription medicines If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for effera?

NutraSmarts rates the evidence for effera as Limited (2 out of 5). It is backed by 4 clinical trials and 6 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(6 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Peterson RD, Guarneiri LL, Adams CG, Wilcox ML, Clark AJ, Rudemiller NP, Maki KC, Malinczak CA. A Randomized, Double-Blind, Controlled Trial to Assess the Effects of Lactoferrin at Two Doses vs. Active Control on Immunological and Safety Parameters in Healthy Adults. Int J Toxicol. 2025;44(1):12-28. doi: 10.1177/10915818241293723.PubMedUsed to support: Randomized double-blind trial in 66 healthy adults: effera 0.34 or 3.4 g a day or bovine lactoferrin 3.4 g a day for 28 days. Anti-bovine lactoferrin antibodies rose about 3-fold with bovine lactoferrin; anti-human lactoferrin antibodies did not change with effera. Safety outcomes were similar between groups. Funded by Helaina.
  2. Peterson RD, van der Made J, Donovan SM, Wang M, Dilger RN, Kaplan N, Clark AJ. Effects of Human Lactoferrin (Effera(®)) at Two Doses Versus Bovine Lactoferrin on the Adult Gut Microbiome and Fecal Short-Chain Fatty Acids: a Randomized, Double-Blind Trial. J Diet Suppl. 2026;23(3):415-439. doi: 10.1080/19390211.2026.2673021.PubMedUsed to support: Exploratory gut analysis of the 66-person trial: diversity stable, some genera increased with effera (Faecalibacterium at the high dose), a higher proportion of acetate with effera, and higher total short-chain fatty acids with bovine lactoferrin. The authors call the findings hypothesis-generating.
  3. Anaya Y, Rosario Martinez R, Goodman RE, Johnson P, Vajpeyi S, Lu X, Peterson R, Weyers SM, Breen B, Newsham K, Scottoline B, Clark AJ, Malinczak CA. Evaluation of the potential food allergy risks of human lactoferrin expressed in Komagataella phaffii. Front Immunol. 2024;15:1380028. doi: 10.3389/fimmu.2024.1380028.PubMedUsed to support: Maker-run allergy risk assessment using literature search, computer sequence comparison, glycan assessment and simulated stomach digestion. No significant cross-reactivity was predicted for the protein or its 36 residual yeast proteins. No testing in people.
  4. Lu X, Cummings C, Osuala UA, Yennawar NH, Namitz KEW, Hellner B, Besada-Lombana PB, Peterson RD, Clark AJ. Characterization of recombinant human lactoferrin expressed in Komagataella phaffii. Analyst. 2024;149(13):3636-3650. doi: 10.1039/d4an00333k.PubMedUsed to support: Laboratory characterization: effera's amino acid sequence is identical to native human lactoferrin and its folded structure closely matches human milk lactoferrin, but its glycans are mainly oligomannose types that differ from human milk lactoferrin.
  5. Ali AS, Hasan SS, Kow CS, Merchant HA. Lactoferrin reduces the risk of respiratory tract infections: A meta-analysis of randomized controlled trials. Clin Nutr ESPEN. 2021;45:26-32. doi: 10.1016/j.clnesp.2021.08.019.PubMedUsed to support: Meta-analysis that reviewed 9 randomized trials and pooled 6 (1,194 participants): lower odds of developing a respiratory tract infection with lactoferrin, odds ratio 0.57 (95% CI 0.44 to 0.74). Two studies had a high risk of bias. None of the trials used effera.
  6. Vitetta L, Coulson S, Beck SL, Gramotnev H, Du S, Lewis S. The clinical efficacy of a bovine lactoferrin/whey protein Ig-rich fraction (Lf/IgF) for the common cold: a double blind randomized study. Complement Ther Med. 2013;21(3):164-71. doi: 10.1016/j.ctim.2012.12.006.PubMedUsed to support: Double-blind trial of 600 mg a day of a bovine lactoferrin and whey immunoglobulin combination in 126 adults with frequent colds (90 completed 90 days). Fewer colds on treatment (48 versus 112, p<0.001), but total days sick and cold severity were not significantly different. A combination product, not effera.